No Data
Analysts Are More Bearish On Innovita Biological Technology Co., Ltd. (SHSE:688253) Than They Used To Be
2025 First Quarter Report
2024 ANNUAL REPORT
2024 Annual Report Summary
InnoTek (688253.SH): The net income for 2024 is 0.247 billion yuan, an increase of 41.9% year-on-year.
On April 25, Glonghui announced that InnoTek (688253.SH) released its 2024 annual report, showing the company's revenue was 0.621 billion yuan, an increase of 30% year-on-year; the Net income attributable to shareholders was 0.247 billion yuan, an increase of 41.9% year-on-year; the Net income attributable to shareholders excluding non-recurring gains and losses was 0.218 billion yuan, an increase of 48.1% year-on-year; the company plans to distribute a cash dividend of 5.6 yuan (including tax) for every 10 shares to all shareholders, with a total distribution amount expected to be 75.23 million yuan, accounting for 30.48% of the Net income.
InnoTek (688253.SH) reported a net income of 95.2897 million yuan in the first quarter, a decrease of 34.77% year-on-year.
Global Union reported on April 25 that InnoTek (688253.SH) released its first quarter report for 2025, achieving revenue of 0.207 billion yuan, a year-on-year decrease of 26.51%; the net income attributable to shareholders of the listed company was 95.2897 million yuan, a year-on-year decrease of 34.77%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 88.3431 million yuan, a year-on-year decrease of 35.58%; the basic EPS was 0.70 yuan.
Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
